INTRODUCTION: Frontotemporal lobar degeneration (FTLD) is classified mainly into FTLD-tau and FTLD-TDP according to the protein present within inclusion bodies. While such a classification implies only a single type of protein should be present, recent studies have demonstrated dual tau and TDP-43 proteinopathy can occur, particularly in inherited FTLD. METHODS: We therefore investigated 33 patients with FTLD-tau (including 9 with MAPT mutation) for TDP-43 pathological changes, and 45 patients with FTLD-TDP (including 12 with hexanucleotide expansion in C9ORF72 and 12 with GRN mutation), and 23 patients with motor neurone disease (3 with hexanucleotide expansion in C9ORF72), for tauopathy. RESULTS: TDP-43 pathological changes, of the kind seen in many elderly individuals with Alzheimer's disease, were seen in only two FTLD-tau cases--a 70-year-old male with exon 10 + 13 mutation in MAPT, and a 73-year-old female with corticobasal degeneration. Such changes were considered to be secondary and probably reflective of advanced age. Conversely, there was generally only scant tau pathology, usually only within hippocampus and/or entorhinal cortex, in most patients with FTLD-TDP or MND. The extent of tau pathology in FTLD-TDP and MND, as with amyloid β protein, may relate to increased age and possession of Apolipoprotein ε4 allele. CONCLUSION: We find no predilection or predisposition towards an accompanying TDP-43 pathology in patients with FTLD-tau, irrespective of presence or absence of MAPT mutation, or that genetic changes associated with FTLD-TDP predispose towards excessive tauopathy. Where the two processes coexist, this is limited and probably causatively independent of each other.
INTRODUCTION: Frontotemporal lobar degeneration (FTLD) is classified mainly into FTLD-tau and FTLD-TDP according to the protein present within inclusion bodies. While such a classification implies only a single type of protein should be present, recent studies have demonstrated dual tau and TDP-43 proteinopathy can occur, particularly in inherited FTLD. METHODS: We therefore investigated 33 patients with FTLD-tau (including 9 with MAPT mutation) for TDP-43 pathological changes, and 45 patients with FTLD-TDP (including 12 with hexanucleotide expansion in C9ORF72 and 12 with GRN mutation), and 23 patients with motor neurone disease (3 with hexanucleotide expansion in C9ORF72), for tauopathy. RESULTS: TDP-43 pathological changes, of the kind seen in many elderly individuals with Alzheimer's disease, were seen in only two FTLD-tau cases--a 70-year-old male with exon 10 + 13 mutation in MAPT, and a 73-year-old female with corticobasal degeneration. Such changes were considered to be secondary and probably reflective of advanced age. Conversely, there was generally only scant tau pathology, usually only within hippocampus and/or entorhinal cortex, in most patients with FTLD-TDP or MND. The extent of tau pathology in FTLD-TDP and MND, as with amyloid β protein, may relate to increased age and possession of Apolipoprotein ε4 allele. CONCLUSION: We find no predilection or predisposition towards an accompanying TDP-43 pathology in patients with FTLD-tau, irrespective of presence or absence of MAPT mutation, or that genetic changes associated with FTLD-TDP predispose towards excessive tauopathy. Where the two processes coexist, this is limited and probably causatively independent of each other.
Authors: Shunsuke Koga; Naomi Kouri; Ronald L Walton; Mark T W Ebbert; Keith A Josephs; Irene Litvan; Neill Graff-Radford; J Eric Ahlskog; Ryan J Uitti; Jay A van Gerpen; Bradley F Boeve; Adam Parks; Owen A Ross; Dennis W Dickson Journal: Acta Neuropathol Date: 2018-06-20 Impact factor: 17.088
Authors: Shunsuke Koga; Monica Sanchez-Contreras; Keith A Josephs; Ryan J Uitti; Neill Graff-Radford; Jay A van Gerpen; William P Cheshire; Zbigniew K Wszolek; Rosa Rademakers; Dennis W Dickson Journal: Mov Disord Date: 2016-12-23 Impact factor: 10.338
Authors: Alexander J Beagle; Sonja M Darwish; Kamalini G Ranasinghe; Alice L La; Elissaios Karageorgiou; Keith A Vossel Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Eun-Joo Kim; Jesse A Brown; Jersey Deng; Ji-Hye L Hwang; Salvatore Spina; Zachary A Miller; Mary G DeMay; Victor Valcour; Anna Karydas; Eliana Marisa Ramos; Giovanni Coppola; Bruce L Miller; Howard J Rosen; William W Seeley; Lea T Grinberg Journal: J Neurol Date: 2018-10-15 Impact factor: 4.849
Authors: Fermin Moreno; Begoña Indakoetxea; Myriam Barandiaran; María Cristina Caballero; Ana Gorostidi; Francesc Calafell; Alazne Gabilondo; Mikel Tainta; Miren Zulaica; José F Martí Massó; Adolfo López de Munain; Pascual Sánchez-Juan; Suzee E Lee Journal: PLoS One Date: 2017-06-08 Impact factor: 3.240
Authors: Shunsuke Koga; Xiaolai Zhou; Aya Murakami; Cristhoper Fernandez De Castro; Matthew C Baker; Rosa Rademakers; Dennis W Dickson Journal: Neuropathol Appl Neurobiol Date: 2021-12-10 Impact factor: 6.250
Authors: Roya Behrouzi; Xiawei Liu; Dongyue Wu; Andrew C Robinson; Sayuri Tanaguchi-Watanabe; Sara Rollinson; Jing Shi; Jinzhou Tian; Hisham H M Hamdalla; John Ealing; Anna Richardson; Matthew Jones; Stuart Pickering-Brown; Yvonne S Davidson; Michael J Strong; Masato Hasegawa; Julie S Snowden; David M A Mann Journal: Acta Neuropathol Commun Date: 2016-03-31 Impact factor: 7.801